Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age19+
SponsorSamsung Medical Center

About this trial

The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy.

The main questions it aims to answer are:

* 5-year disease-free survival * 5-year overall survival * 5-year locoregional recurrence * Adverse events after radiation therapy * Quality of life

Participants will be assessed by multi-dimensional methods before and after radiotherapy:

* Disease status evaluation including physical and radiological examination * Quality of life assessment with questionnaires (BREAST-Q) * Adverse event assessment according to CTCAE version 5.0

Eligibility criteria

Qualifiers

Female with age 19 or older

Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy

Underwent neoadjuvant chemotherapy

Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy

Disqualifiers

Previous history of radiation therapy to the chest

Distant metastasis

Trial design

Treatments tested in this trial

  • Whole breast / chest wall & regional lymph node irradiation
  • Internal mammary or supraclavicular lymph node boost

Treatment groups

120 Participants
are divided into 1 treatment group

Sponsors and collaborators